renal cancer
Conditions
Interventions
Administration of 5 mg/37 MBq zirconium-89-girentuximab followed by PET/CT
after 4 days.
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: His or her clinician should face a diagnostic dilemma; - patients with a renal mass of unknown origin, or - patients with a primary renal mass in whom it is unclear whether there is metastatic disease, or - patients with a history of clear cell RCC with a suspicion of relapse or metastatic disease. * Age over 18 years;Signed informed consent
Exclusion criteria
Exclusion criteria: History of a CAIX-negative or non clear cell RCC. Administration of tyrosine kinase inhibiters within 1 month prior to inclusion. Known hypersensitivity or HACA against Girentuximab.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Impact on clinical decision making, defined as present or absent: * Absent: e.g. no change in treatment or follow-up * Present: e.g. change in follow-up schedule, change in surgical technique, be more certain of your treatment strategy, change from surgery to active surveillance, or change from surgery to systemic treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| The amount of biopsies or surgery that are prevented by zirconium-89-girentuximab PET/CT. * | — |
Countries
Netherlands
Outcome results
None listed